

MEDICAL POLICY

MEDICAL POLICY DETAILS	
Medical Policy Title	Balloon Sinus Ostial Dilation for Treatment of Chronic Rhinosinusitis (i.e., Balloon Sinuplasty)
Policy Number	7.01.85
Category	Technology Assessment
Original Effective Date	04/21/11
Committee Approval Date	06/21/12, 05/23/13, 06/19/14, 06/18/15, 06/16/16, 06/15/17, 05/17/18, 05/16/19, 05/21/20, 05/20/21, 06/16/22, 08/17/23
Current Effective Date	12/15/23
Archived Date	N/A
Archived Review Date	N/A
Product Disclaimer	<ul style="list-style-type: none"> • <i>If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.</i> • <i>If a commercial product (including an Essential Plan or Child Health Plus product), medical policy criteria apply to the benefit.</i> • <i>If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit.</i> • <i>If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.</i> • <i>If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.</i>

POLICY STATEMENT

- I. Based upon our criteria and assessment of the peer-reviewed literature, balloon sinus ostial dilation (also known as balloon sinuplasty) or any other catheter-based inflatable device, as a stand-alone procedure, has been medically proven to be effective and, therefore, is considered **medically appropriate** for the treatment of chronic rhinosinusitis when **ALL** the following criteria have been met:
- Documentation of two (2) or more of the following cardinal signs/symptoms of chronic rhinosinusitis (CRS) symptoms for greater than three (3) months:
 - Nasal obstruction (congestion); or
 - Nasal mucopurulent drainage (anterior and/or posterior); or
 - Facial pain, pressure, fullness; or
 - Decreased or loss of sense of smell; **AND**
 - Documentation of failed medical therapy with **ALL** the following:
 - Steroid nasal spray for at least 8-weeks;
 - Saline nasal irrigation/lavage for at least 8-weeks;
 - Antibiotics are only required when a bacterial infection is suspected; **AND**
 - Only for patients with documented chronic rhinosinusitis with nasal polyps (CRSwNP), at least one 10-day course of oral corticosteroids is required; **AND**
 - Objective evidence of chronic rhinosinusitis in following optimal medical therapy, documented by **ONE** of the following:
 - Nasal endoscopy findings of purulent [not clear] mucus, or edema in the middle meatus or anterior ethmoid region; or polyps in the nasal cavity or in the middle meatus; **AND/OR**
 - Sinus computerized tomography (CT) findings of air fluid levels, nasal polyps, opacification, **OR** mucosal thickening greater than two (2) millimeters (also referred to as mild mucosal thickening).

Medical Policy: BALLOON SINUS OSTIAL DILATION FOR TREATMENT OF RHINOSINUSITIS (e.g., BALLOON SINUPLASTY)

Policy Number: 7.01.85

Page: 2 of 6

- II. Based upon our criteria and assessment of the peer-reviewed literature, balloon sinus ostial dilation or any other catheter-based inflatable device has not been medically proven to be effective and, therefore, is considered **investigational** for treating recurrent acute rhinosinusitis (RAS).
- III. Based upon our criteria and the lack of peer-reviewed literature, self-expanding absorptive sinus ostial dilation (e.g., SinuSys Vent-OS) has not been medically proven to be effective and, therefore, is considered **investigational** for all indications.

Refer to Corporate Medical Policy #11.01.03 Experimental and Investigational Services

POLICY GUIDELINES

- I. Along with the four (4) cardinal symptoms of CRS, individuals may also experience non-specific symptoms (e.g., fatigue, cough, ear pain/pressure, halitosis, dental pain, nasal/throat irritation, or sleep disturbance).
- II. If balloon sinuplasty is performed in conjunction with another sinus surgery in the same sinus, the balloon dilation would be considered inclusive/incidental to the primary procedure, and, therefore, would not be reimbursed separately.
- III. Balloon sinuplasty is limited to the frontal, maxillary, or sphenoid sinuses.
- IV. Balloon sinuplasty can relieve symptoms for patients with CRSwNP; however, severe/gross polyposis may require biologic therapy and/or polypectomy.

DESCRIPTION

Chronic rhinosinusitis (CRS) is an inflammatory condition of the paranasal sinuses and linings of the nasal passages that persists for at least 12 weeks. The four cardinal signs/symptoms are listed above in Policy Statement I, with other symptoms being too non-specific for the diagnosis of CRS (e.g., cough, ear pain, headache, fatigue, or throat irritation). CRS can be divided into three subtypes: CRS without nasal polyposis (CRSsNP), CRS with nasal polyposis (CRSwNP), allergic fungal rhinosinusitis (AFRS). These four cardinal symptoms may be present with any subtype of disease and do not differentiate among the subtypes of CRS.

Functional endoscopic sinus surgery (FESS), used when a patient fails to respond to aggressive medical management, has become an important aspect of surgical management of chronic rhinosinusitis. Balloon ostial dilation (balloon sinuplasty) is an alternative to functional endoscopic sinus surgery (FESS) for treatment of chronic rhinosinusitis or recurrent acute rhinosinusitis. The procedure can be performed as a stand-alone procedure or with FESS. When performed with FESS, it may be referred to as a hybrid procedure.

Balloon ostial dilation involves placing a guidewire in the sinus ostium (confirmed with fluoroscopy or with direct transillumination of the targeted sinus cavity), advancing a balloon over the guidewire, and then stretching the sinus opening by inflating the balloon. The procedure aims to restore sinus drainage and function without damaging the sinus mucosa. Pressure caused by the inflated balloon restructures and widens the ostium by creating microfractures in the surrounding bone. General anesthesia may be needed to minimize patient movement; however, an increasing number of ENT doctors perform the procedure in the office under local anesthesia.

Self-expanding absorptive sinus ostial dilation has been proposed as an alternative to balloon sinus ostial dilation. The self-expanding device is inserted into the sinus ostia to allow for a more gradual dilation through an osmotic process using the body's natural mucosal fluids to expand the insert before removal. Once inserted, the device absorbs moisture from the surrounding tissue and begins to expand, providing low-pressure, gradual dilation of the sinus ostia. Once the device has been given enough time to fully expand, it is removed. This type of device is proposed to maximize patient tolerability of the procedure.

RATIONALE

In March 2008, the device "Relieva Sinus Balloon Catheter" (Acclarent, Menlo Park, CA) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. The FDA determined that this device was substantially equivalent to existing devices for use in dilating the sinus ostia and paranasal spaces in adults and maxillary

Medical Policy: BALLOON SINUS OSTIAL DILATION FOR TREATMENT OF RHINOSINUSITIS (e.g., BALLOON SINUPLASTY)

Policy Number: 7.01.85

Page: 3 of 6

sinus spaces in children. Subsequent devices developed by Acclarent have also been granted 510(k) marketing clearance. These include the Relieva Spin Sinus Dilation System, cleared in August 2011, and the Relieva Seeker Balloon Sinuplasty System, cleared in November 2012. In June 2008, the FinESS Sinus Treatment (Entellus Medical, Inc., Maple Grove, MN) was cleared for marketing by the FDA through the 510(k) process. The indication noted is to access and treat the maxillary ostia/ethmoid infundibula in adults using a transantral approach. The bony sinus outflow tracts are remodeled by balloon displacement of adjacent bone and paranasal sinus structures. Two other balloon sinus ostial dilation devices by Entellus Medical, Inc. also received 510(k) approval in August 2012. These are the ENTrigue Sinus Dilation System and the XprESS Multi-Sinus Dilation Tool. In late 2013, the NuVent EM Balloon Sinus Dilation System (Medtronic) received FDA 510(k) clearance. It features a built-in electromagnetic surgical navigation technology.

In January 2014, the Vent-Os-Gentle Sinus Dilation System (SinuSys Corporation) received FDA clearance based on comparison to predicate devices. The Vent-Os System incorporates the Company's proprietary osmotic technology, which utilizes the body's natural mucosal fluids to expand the insert before removal. The Vent-Os System achieved post-procedural patency in 95 percent of the sinus ostia treated in a multi-center study and submitted as part of the developer's FDA application. Currently, there are no published studies in peer-reviewed literature addressing this device. Additionally, while there are multiple guidelines, recommendations, and consensus statements regarding the treatment of rhinosinusitis from professional societies (e.g., American Academy of Otolaryngology - Head and Neck Surgery and the American Rhinologic Society), these documents do not mention the SinuSys Vent-OS device.

In January 2023, the American Rhinologic Society (ARS) issued a position statement supporting the use of balloon sinus ostial dilation as a therapeutic option for selected patients with CRS and RARS who have failed appropriate medical therapy. Their support of this treatment is based on clinical consensus statements and primary research evidence. Per the position statement, the clinical diagnosis of CRS and RARS should be based on symptoms of sinusitis and supported by objective evidence (nasal endoscopy documenting sinonasal abnormality or mucosal thickening on CT scan of the paranasal sinuses) prior to considering the use of balloon sinus dilation. The ARS concluded this approach may be used alone or in conjunction with traditional endoscopic sinus surgery.

The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) published its current Clinical Consensus Statement for balloon dilation of the sinuses in 2018 (Piccirillo et al.). Based on a systematic review of the literature and expert consensus, the AAO-HNS reached consensus on a total of 13 statements regarding proper setting and safeguards for performing the procedure. The AAO-HNS's current Clinical Practice Guidelines for Adult Sinusitis was published in 2015 (Rosenfeld et al.).

Sikand et al. (2019) addressed the limited number of studies that have demonstrated symptomatic improvement for recurrent acute rhinosinusitis (RARS). This randomized sham-controlled study evaluated outcomes for balloon sinus dilation (BSD) with medical management (MM) (n = 29) as compared with MM only (n = 30) for patients diagnosed with RARS. Patients were followed through 48 weeks post-procedure, with the primary endpoint being the difference in the change in Chronic Sinusitis Survey (CSS) score from baseline to 24 weeks between the 2 cohorts. The authors concluded that BSD plus MM proved superior to MM alone in enhancing QOL for RARS patients. According to the authors, BSD plus MM should be considered as a viable treatment option for properly diagnosed RARS patients. However, the authors reported the limited ability to perform meaningful comparisons between groups after 24-week follow-up due to 60% crossover in the MM arm, lack of an objective measure to assess staging of the disease, lack of properly validated instruments for RARS, high number of frontal sinuses performed, and conflicts of interest among the investigators.

Chandra et al. (2016) reported the final results from the REMODEL full-study cohorts and performed meta-analyses of standalone balloon sinus dilation studies to explore long-term outcomes in a large patient sample. Final outcomes from the REMODEL randomized trial, including a larger cohort of 135 patients treated with functional endoscopic sinus surgery (FESS) or in-office balloon dilation, were evaluated. All patients met the definition of medically refractory chronic rhinosinusitis (CRS) according to the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) clinical practice guidelines. In the meta-analysis of standalone balloon dilation studies, technical success is 97.5%, and mean 20-item Sino-Nasal Outcomes Test scores were significantly and clinically improved at all time points. The meta-analysis included a subgroup analysis for patients with chronic rhinosinusitis (n=191) versus recurrent acute rhinosinusitis (n=52). Both groups experienced statistically significant and clinically meaningful improvements in mean SNOT-20 scores, with no significant difference between groups. The authors concluded that all outcomes are comparable between

Medical Policy: BALLOON SINUS OSTIAL DILATION FOR TREATMENT OF RHINOSINUSITIS (e.g., BALLOON SINUPLASTY)

Policy Number: 7.01.85

Page: 4 of 6

FESS and balloon dilation at all time points from six months to 24 months. According to the authors, balloon dilation produces faster recovery, less postoperative pain, and fewer debridements than FESS.

There is evidence that balloon sinuplasty can be performed successfully and safely in adult patients with chronic rhinosinusitis in both the outpatient setting and the provider office setting. Clinical studies identify improvement in symptoms that are like FESS, and potential advantages for balloon sinuplasty with respect to on postoperative recovery time and pain medication use.

There is insufficient evidence to determine that balloon ostial dilation (balloon sinuplasty) results in an improvement in the net health outcome for the treatment of recurrent acute rhinosinusitis.

CODES

- Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.
- **CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.**
- Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.
- Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).

CPT Codes

Code	Description
31295	Nasal/sinus endoscopy, surgical, with dilation (e.g., balloon dilation); maxillary sinus ostium, transnasal or via canine fossa
31296	Nasal/sinus endoscopy, surgical, with dilation (e.g., balloon dilation); frontal sinus ostium
31297	Nasal/sinus endoscopy, surgical, with dilation (e.g., balloon dilation); sphenoid sinus ostium
31298	Nasal/sinus endoscopy, surgical, with dilation (e.g., balloon dilation); frontal and sphenoid sinus ostia
31299 (*E/I)	Unlisted procedure, accessory sinuses *E/I when billing for self-expanding absorptive sinus ostial dilation

Copyright © 2023 American Medical Association, Chicago, IL

HCPCS Codes

Code	Description
C1726	Catheter, balloon dilatation, nonvascular

ICD10 Codes

Code	Description
J32.0-J32.9	Chronic sinusitis (code range)

REFERENCES

*American Academy of Otolaryngology Head and Neck Surgery. Academy continues advocacy on balloon sinus ostial dilation. 2019 Jan. Updated 2021 Apr. [<https://www.entnet.org/news/academy-continues-advocacy-on-balloon-sinus-ostial-dilation-1-23-2019/>] accessed 05/09/23.

American Rhinologic Society (ARS). Ostial balloon dilation position statement. Mar 14, 2017. Updated Jan 2023. [<https://www.american-rhinologic.org/position-statements>] accessed 05/11/23.

*Brietzke S, et al. Clinical consensus statement: pediatric chronic rhinosinusitis. Otolaryngol Head Neck Surg 2014 Oct;151(4):524-553.

Medical Policy: BALLOON SINUS OSTIAL DILATION FOR TREATMENT OF RHINOSINUSITIS (e.g., BALLOON SINUPLASTY)

Policy Number: 7.01.85

Page: 5 of 6

*Bolger WE, et al. Safety and outcomes of balloon catheter sinusotomy: a multicenter 24-week analysis in 115 patients. Otolaryngol Head Neck Surg 2007 Jul;137(1):10-20.

Castro A, et al. Long term outcomes of balloon sinuplasty for the treatment of chronic rhinosinusitis with and without nasal polyps. Journal of Otolaryngology 2021 Jan-Feb;42(1):1-5.

*Chandra RK, et al. REMODEL larger cohort with long-term outcomes and meta-analysis of standalone balloon dilation studies. Laryngoscope 2016 Jan;126(1):44-60.

*Cutler J, et al. First clinic experience: patient selection and outcomes for ostial dilation for chronic rhinosinusitis. Int Forum Allergy Rhinol 2011 Nov-Dec;1(6):460-5.

*Friedman M, et al. Functional endoscopic dilatation of the sinuses: patient satisfaction, postoperative pain, and cost. Am J Rhinology 2008 Mar-Apr;22(2):204-9.

Higgins TS, et al. "In-office balloon sinus ostial dilation with concurrent antiplatelet and anticoagulant therapy for chronic rhinosinusitis without nasal polyps". Annals of Otolaryngology, Rhinology & Laryngol 2020;129(3):280–286.

Jia L, et al., 3-year follow-up after balloon sinuplasty in children with chronic rhinosinusitis. International Journal of Pediatric Otorhinolaryngology 2020 Sept 136: 1-7.

*Kim E, et al. Balloon dilatation of the paranasal sinuses: a tool in sinus surgery. Otolaryngol Clin North Am 2009 Oct;42(5):847-56.

*Kizhner V, et al. Transantral balloon dilation plus posterior ethmoidectomy. Laryngoscope 2011 May;121(5):1108-11.

Koskinen A, et al. Long-term follow-up after maxillary sinus balloon sinuplasty and ESS. Ear, Nose & Throat Journal 2021 Feb: 1-7.

*Kuhn FA, et al. Balloon catheter sinusotomy: one year follow-up- outcomes and role in functional endoscopic sinus surgery. Otolaryngol Head Neck Surg 2008 Sep;139(3 Suppl 3):S27-37.

*Kutluhan A, et al. Endoscopic balloon dilation sinuplasty including ethmoidal air cells in chronic rhinosinusitis. Ann Oto Rhinol Laryngol 2009 Dec;118(12):881-6.

Levine SB, et al. In-office stand-alone balloon dilation of maxillary sinus ostia and ethmoid infundibula in adults with chronic or recurrent acute rhinosinusitis: a prospective, multi-institutional study with 1-year follow-up. Annals of Otolaryngology, Rhinology & Laryngol 2013;122(11):665-671.

Liu J et al. 3-year follow-up after balloon sinuplasty in children with chronic rhinosinusitis. Intern J of Ped Otorhinolaryngol 2020 Sep; 136:110084.

Lofgren DH, Shermetaro C. Balloon Sinuplasty [Updated 2022 Sep 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. [<https://www.ncbi.nlm.nih.gov/books/NBK546671/>] accessed 05/19/23.

*National Institute for Health and Clinical Excellence (NICE). Balloon catheter dilation of paranasal sinus ostia for chronic sinusitis. 2008 Sep [<https://www.nice.org.uk/guidance/ipg273>] accessed 05/19/23.

Orlandi RR, et al. International consensus statement on allergy and rhinology: rhinosinusitis executive summary. Int Forum Allergy Rhinol 2016 Feb;6 Suppl 1:S3-S21.

Piccirillo JF, et al. Consensus statement balloon dilation of the sinuses. Otolaryngol Head Neck Surg Feb 2018;158(2):203-214. Accessed 05/05/23

*Plaza G, et al. Balloon dilation of the frontal recess: a randomized clinical trial. Ann Otol Rhinol Laryngol 2011 Aug;120(8):511-8.

*Ramadan HH. Safety and feasibility of balloon sinuplasty for treatment of chronic rhinosinusitis in children. Ann Otol Rhinol Laryngol 2009 Mar;118(3):161-5.

*Ramadan HH, et al. Balloon catheter sinuplasty in young children. Am J Rhinol Allergy 2010 Jan-Feb;24(1):e54-6.

Medical Policy: BALLOON SINUS OSTIAL DILATION FOR TREATMENT OF RHINOSINUSITIS (e.g., BALLOON SINUPLASTY)

Policy Number: 7.01.85

Page: 6 of 6

*Ramadan HH, et al. Balloon catheter sinuplasty and adenoidectomy in children with chronic rhinosinusitis. Ann Otol Rhinol Laryngol 2010 Sep;119(9):578-82.

Rank MA, et al. The joint task force on practice parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. J of Allergy and Clin Imm 2023 Feb;151(2):386-398.

*Rosenfeld R, et al. Clinical practice guideline (update): adult sinusitis. Otolary Head Neck Surg 2015 Apr 152(2) [<https://journals.sagepub.com/doi/full/10.1177/0194599815572097>] accessed 05/11/23.

Sikand A, et al. In-office balloon sinus dilation versus medical therapy for recurrent acute rhinosinusitis: a randomized, placebo-controlled study. International Forum of Allergy & Rhinology 2019 Feb;9(2):140-148.

Sinnott J and Chisholm E. Balloon sinuplasty: two-year follow up using sino-nasal outcome test-22 outcomes. J Laryngol Otol 2021 May;135(5):415-419.

Smith SS et al. Is there a role for antibiotics in the treatment of chronic rhinosinusitis? J of Allergy and Clin Immunology 2022 Feb;149(5):1504-1512. [doi.org/10.1016/j.jaci.2022.02.004] accessed 06/05/23.

*Stewart AE, et al. Balloon sinuplasty vs surgical management of chronic rhinosinusitis. Curr Allergy Asthma Rep 2010 May;10(3):181-7.

Stolovitzky JP, et al. Medical therapy versus balloon sinus dilation in adults with chronic rhinosinusitis (MERLOT): 12-month follow-up. Am J Rhinol Allergy 2018 Jul; 32(4): 294-302.

Thong G, et al. Balloon sinuplasty utilization in the pediatric population: a national database perspective. Otolaryngology Head and Neck Surgery 2019;161(4):683-687.

*Vaughan WC. Review of balloon sinuplasty. Curr Opin Otolaryngol Head Neck Surg 2008 Feb;16(1):2-9.

*Weiss RL, et al. Long-term outcome analysis of balloon catheter sinusotomy: two-year follow-up. Otolaryngol Head Neck Surg 2008 Sep;139(3 Suppl 3):S38-46.

Zalzal HG, et al. Long-term effectiveness of balloon catheter sinuplasty in pediatric chronic maxillary sinusitis. Ear Nose Throat J 2019 May;98(4):207-211.

*Key Article

KEY WORDS

Balloon sinuplasty, balloon dilation, catheter sinusotomy, chronic rhinosinusitis, recurrent acute rhinosinusitis

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

Based upon our review, sinus ostial dilation/balloon sinuplasty is not addressed in National or Regional CMS coverage determinations or policies.